Rheaplant raises fresh funding from Big Idea Ventures to scale plant cell culture for food
What's the deal? Rheaplant, a startup growing plant cells in bioreactors to produce high-value food and nutraceutical ingredients, has secured fresh funding from Big Idea VenturesDealroom has a profile for this one. Try Dealroom →. The company, founded in January 2025 by chief technology officer Derek Scholin and chief executive officer Sowmya Purushothaman, previously raised a small check from 2045 VenturesDealroom has a profile for this one. Try Dealroom → last summer.
Rather than nurturing fully grown plants with sunlight and soil, Rheaplant grows plant cells in controlled bioreactor environments to produce bioactives like ashwagandha, rhodiola, and American ginseng. It now has 13 cell lines in culture and is also exploring colorants, alternative sweeteners, and other ingredients.
Why now? Traditional botanical supply chains are under growing pressure from unpredictable weather, political instability, and soil contamination. "When we talk to potential clients in the botanicals space, some of them are distraught," says Scholin. "They say things like: 'One year we didn't have a product.'"
Many of these compounds are too complex for precision fermentation using microbes, making plant cell culture potentially the only viable alternative. Growing them in bioreactors also eliminates heavy metals that plants can absorb from soil outdoors.
What could go wrong? The core challenge is cost. Plant cell culture is well established in pharmaceuticals — it produces the breast cancer drug Taxol — but pharma-grade equipment and processes are too expensive for food and nutraceutical margins.
Rheaplant is betting on a modular, distributed bioreactor approach using 2,000–5,000-litre reactors and semi-continuous processing rather than massive steel tanks. Oxygen transfer becomes harder as tanks get bigger, especially because plant cells are larger than microbial cells and tend to aggregate.
The company is also developing proprietary non-steam-based sterilisation technology to cut costs. "The pharmaceutical grade approach is robust but it's not going to work for the food sector," says Purushothaman.
Optimising bioactive production still involves significant trial and error. Rheaplant is working with Oregon State University on analytics, but reliably scaling semi-continuous processing remains unproven — the company still needs to determine how many batches can run reliably at scale.
The signal: Rheaplant joins a small but growing cadre of startups trying to extend plant cell culture beyond pharma into food ingredients. The bet is that purpose-built, food-grade facilities without biopharma cost structures could unlock unit economics that broaden the technology's reach over the next decade.
If the modular approach works, it could offer a resilient, climate-independent production model for high-value botanicals — a meaningful shift for an industry plagued by supply chain fragility.
Read more: AgFunderNews
